Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Human Vaccines & Immunotherapeutics|February 5, 2021
Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine：a phase I clinical trialZhi-Wei Wu, Qing-Liang Li, Hai-Song Zhou, et al.
Human Vaccines & Immunotherapeutics|June 17, 2022
Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trialXiaoyuan Huang, Ting Fan, Li Li, et al.
Virologica Sinica|May 8, 2022
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variantsJia Lu, Qiangling Yin, Rongjuan Pei, et al.
Antiviral Research|June 3, 2023
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical studyJiayou Zhang, Xuanxuan Nian, Bo Liu, et al.
Human Vaccines & Immunotherapeutics|May 30, 2023
Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical studyXiaoyuan Huang, Jing Liang, Lili Huang, et al.
Frontiers in Neural Circuits|January 10, 2022
Neurotensin Attenuates Nociception by Facilitating Inhibitory Synaptic Transmission in the Mouse Spinal CordMing-Ming Zhang, Yu-Peng Feng, Xin-Tong Qiu, et al.
Human Vaccines & Immunotherapeutics|June 17, 2022
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trialJinhua Chen, Pengfei Jin, Xiaoqi Chen, et al.
Human Vaccines & Immunotherapeutics|October 16, 2023
Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trialZhi-Wei Wu, Fei Jin, Qing-Liang Li, et al.
Emerging Microbes & Infections|November 16, 2023
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in ChinaYing Liu, Jiayou Zhang, Wen Liu, et al.
Vaccines|July 27, 2024
The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 MiceJie Yang, Huifen Fan, Anna Yang, et al.
Pageof 11